Search | Clinical Trials Finder

Conditions: Cough, Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 67
States / cities: Jasper, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 59 more

Conditions: Ulcerative Colitis
Interventions: abatacept (ABA), placebo, abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more

Conditions: Post-Traumatic Stress Disorder
Interventions: levetiracetam, Placebo, Levetriracetam; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Phenylketonuria
Interventions: tetrahydrobiopterin (BH4); Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 10 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 11 more

Conditions: Food Hypersensitivity
Interventions: Peanut SLIT, Placebo SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Encino, California • Newport Beach, California • San Diego, California + 7 more

Conditions: HBeAg-negative Chronic Hepatitis B
Interventions: TAF, TDF, TAF Placebo, TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more

Conditions: Sarcoidosis, Cardiac
Interventions: Namilumab; Drug
Lead sponsor: Kinevant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 12
States / cities: Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Healthy Volunteers
Interventions: Placebo, LY3031207, Celecoxib, Simvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Treatment of Type I Diabetes Mellitus.
Interventions: Biological; Biological
Lead sponsor: DiaVacs, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Kidney Failure
Interventions: Fermagate, Placebo; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina

Conditions: Schizophrenia
Interventions: LY2140023, Placebo; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Oakland, California • San Diego, California • Torrance, California + 5 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo-matched-to-ivacaftor tablet; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Healthy
Interventions: TRV130, Moxifloxacin, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 54
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Major Depressive Disorder
Interventions: NBI-1065845, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Oceanside, California • Orange, California • San Jose, California + 21 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more

Conditions: PCDH19-Related Epilepsy
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more

Conditions: Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions: Givosiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions: RSVpreF, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 36
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more

Search by objective public record fields.

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Study of Abatacept in Patients With Active Ulcerative Colitis

Levetiracetam in Post-Traumatic Stress Disorder

Response to Phenylketonuria to Tetrahydrobiopterin (BH4)

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

A Study of Sublingual Immunotherapy in Peanut-allergic Children

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

A Multiple-dose Study of LY3031207 in Healthy Participants

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

A Physical Dependence Study in Schizophrenia

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease